European Pharmaceutical Review

SEPTEMBER 28, 2023

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Manufacturing 81

Manufacturing Government Pharmaceutical manufacturing Pharmaceutical 81

European Pharmaceutical Review

OCTOBER 12, 2023

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.

Pharmaceutical manufacturing 82

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 82

European Pharmaceutical Review

JULY 21, 2023

In this Q&A EPR speaks to Naser Al Yammahi the Deputy CEO of Hayat Biotech about pharmaceutical supply chain challenges and how they can be addressed. Yammahi was instrumental in building Hayat’s extensive distribution network needed to supply vaccines during the COVID-19 pandemic.

Pharmaceutical 93

Pharmaceutical Food and Drug Administration Transportation Manufacturing 93

Clarify Health

OCTOBER 26, 2021

Not Enrolled Given this historical backdrop, the FDA and leading biotech and pharmaceutical manufacturers have taken initiatives to ensure: representative clinical trial recruitment that reflects the broader US patient population and equitable access to therapies and vaccines. J National Comprehensive Cancer Network.

Food and Drug Administration 52

Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52

pharmaphorum

OCTOBER 26, 2022

The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We As a result, society and government bodies have not developed models and policies that adequately support the development of and access to rare disease drugs.”. About the author.

Patients 77

Patients Pharma Consulting Transportation 77

pharmaphorum

JANUARY 24, 2023

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. ” Image from the Association of the British Pharmaceutical Industry (ABPI). Notable examples include a pair of 10-year alliances with mRNA specialists Moderna and BioNTech.

Manufacturing 105

Manufacturing Medicine Government Pharmaceutical manufacturing 105